Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes

• Published in: BMC cancer Vol. 12; no. 1; p. 174
• Main Authors: Shieh, Shwn-Huey, Probst, Janice C, Sung, Fung-Chang, Tsai, Wen-Chen, Li, Ya-Shin, Chen, Chih-Yi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11-05-2012; BioMed Central; BMC
• Subjects: Adult; Aged; Aged, 80 and over; Cancer; Cancer patients; Care and treatment; Comorbidity; Diabetes; Diabetics; Female; Health aspects; Hospitals; Humans; Lung cancer; Lung Neoplasms - epidemiology; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Medical centers; Medical research; Middle Aged; Mortality; Neoplasm Staging; Oncology, Experimental; Patient outcomes; Smoking; Survival; Tuberculosis; China
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/1471-2407-12-174

Comorbid conditions influence the survival of cancer patients. This study evaluated the influence of comorbidity on survival among lung cancer patients.
The authors evaluated the medical records of 1111 lung cancer patients of a medical center in Taiwan. Days of survival were calculated for each patient and mortality hazard ratios were estimated for associations with demographic status, comorbidity and cancer stage at diagnosis.
On average, the survival time was slightly longer among women than among men (838±689 vs. 749±654 days, p = 0.050). Survival days increased with age (from 580±526 [≤ 50 years] to 803±693 [≥ 71 years] days, p = 0.020) and decreased with stage (from 1224±656 [stage I] to 489±536 [stage IV] days, p < 0.001). Younger patients were more likely to be diagnosed with lung cancer at a late stage. Compared with lung cancer patients without tuberculosis, those with tuberculosis had a significantly shorter average survival duration (584 vs. 791 days, p = 0.002) and a higher mortality hazard ratio (1.30, 95% CI: 1.03 - 1.65). A similar trend was observed in lung cancer patients with diabetes.
Lung cancer patients with comorbid tuberculosis or diabetes are at an elevated risk of mortality. These patients deserve greater attention while undergoing cancer treatment.